Antibiotic Drug Development: Moving Forward into the Clinic

2011 ◽  
pp. 1071-1100 ◽  
Author(s):  
Jane E. Ambler ◽  
Greg G. Stone

Author(s):  
Sreedharan N. Sabarinath ◽  
Rajendra Pratap Singh ◽  
Hartmut Derendorf


2011 ◽  
Vol 10 (5) ◽  
pp. 454-460 ◽  
Author(s):  
Aaron Dane




2020 ◽  
Vol 12 (22) ◽  
pp. 2035-2065
Author(s):  
Liam J Stephens ◽  
Melissa V Werrett ◽  
Adam C Sedgwick ◽  
Steven D Bull ◽  
Philip C Andrews

As bacteria continue to develop resistance to our existing treatment options, antibiotic innovation remains overlooked. If current trends continue, then we could face the stark reality of a postantibiotic era, whereby routine bacterial infections could once again become deadly. In light of a warning signaled by the WHO, a number of new initiatives have been established in the hope of reinvigorating the antibiotic drug development pipeline. In this perspective, we aim to summarize some of these initiatives and funding options, as well as providing an insight into the predicament that we face. Using clinical trials data, company website information and the most recent press releases, a current update of the antibiotic drug development pipeline is also included.





2018 ◽  
Vol 154 (6) ◽  
pp. S-1040 ◽  
Author(s):  
Judith Wendler ◽  
Björn O. Schröder ◽  
Dirk Ehmann ◽  
Christina Braunsdorf ◽  
Nisar P. Malek ◽  
...  


2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Jeannine Hess

Abstract The occurrence of drug-resistant bacteria is drastically rising and new and effective antibiotic classes are urgently needed. However, most of the compounds in development are minor modifications of previously used drugs to which bacteria can easily develop resistance. The investigation of inorganic and organometallic compounds as antibiotics is an alternative approach that holds great promises due to the ability of such molecules to trigger metal-specific mechanisms of action, which results in lethal consequences for pathogens. In this review, a selection of concepts to rationally design inorganic and organometallic antibiotics is discussed, highlighting their advantages by comparing them to classical drug discovery programmes. The review concludes with a short perspective for the future of antibiotic drug development and the role metal-based compounds will play in the field.



2016 ◽  
Vol 24 (24) ◽  
pp. 6446-6451 ◽  
Author(s):  
Michael S. Sinha ◽  
Aaron S. Kesselheim


Sign in / Sign up

Export Citation Format

Share Document